Cargando…

Xpert Ultra Can Unambiguously Identify Specific Rifampin Resistance-Conferring Mutations

Detalles Bibliográficos
Autores principales:	Ng, Kamela C. S., van Deun, Armand, Meehan, Conor J., Torrea, Gabriela, Driesen, Michèle, Gabriëls, Siemon, Rigouts, Leen, André, Emmanuel, de Jong, Bouke C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2018
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113491/ https://www.ncbi.nlm.nih.gov/pubmed/29925643 http://dx.doi.org/10.1128/JCM.00686-18

Ejemplares similares

Variable ability of rapid tests to detect Mycobacterium tuberculosis rpoB mutations conferring phenotypically occult rifampicin resistance
por: Torrea, Gabriela, et al.
Publicado: (2019)

False Rifampicin Resistance in Xpert Ultra Applied to Lymph Node Aspirate: A Case Report
por: Ng, Kamela C S, et al.
Publicado: (2020)

GeneXpert MTB/RIF Ultra performance to detect uncommon rpoB mutations in Mycobacterium tuberculosis
por: Rigouts, Leen, et al.
Publicado: (2023)

Potential Application of Digitally Linked Tuberculosis Diagnostics for Real-Time Surveillance of Drug-Resistant Tuberculosis Transmission: Validation and Analysis of Test Results
por: Ng, Kamela Charmaine, et al.
Publicado: (2018)

How Well Do Routine Molecular Diagnostics Detect Rifampin Heteroresistance in Mycobacterium tuberculosis?
por: Ng, Kamela C. S., et al.
Publicado: (2019)

Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations
por: Lempens, Pauline, et al.
Publicado: (2018)

Acquired rifampicin resistance during first TB treatment: magnitude, relative importance, risk factors and keys to control in low-income settings
por: Van Deun, Armand, et al.
Publicado: (2022)

Initial resistance to companion drugs should not be considered an exclusion criterion for the shorter multidrug-resistant tuberculosis treatment regimen
por: Lempens, Pauline, et al.
Publicado: (2020)

Borderline rpoB mutations transmit at the same rate as common rpoB mutations in a tuberculosis cohort in Bangladesh
por: Lempens, Pauline, et al.
Publicado: (2023)

Correlation of different phenotypic drug susceptibility testing methods for four fluoroquinolones in Mycobacterium tuberculosis
por: Coeck, Nele, et al.
Publicado: (2016)

Low Cycle Threshold Value in Xpert MTB/RIF Assay May Herald False Detection of Tuberculosis and Rifampicin Resistance: A Study of Two Cases
por: Ngabonziza, Jean Claude S, et al.
Publicado: (2021)

Storage of Sputum in Cetylpyridinium Chloride, OMNIgene.SPUTUM, and Ethanol Is Compatible with Molecular Tuberculosis Diagnostic Testing
por: Sanoussi, C. N’Dira, et al.
Publicado: (2019)

Tuberculosis Variant with Rifampin Resistance Undetectable by Xpert MTB/RIF, Botswana
por: Modongo, Chawangwa, et al.
Publicado: (2023)

GeneXpert MTB/RIF Assay for the Diagnosis of Tuberculous Lymphadenitis on Concentrated Fine Needle Aspirates in High Tuberculosis Burden Settings
por: Tadesse, Mulualem, et al.
Publicado: (2015)

The New Xpert MTB/RIF Ultra: Improving Detection of Mycobacterium tuberculosis and Resistance to Rifampin in an Assay Suitable for Point-of-Care Testing
por: Chakravorty, Soumitesh, et al.
Publicado: (2017)

Spot specimen testing with GeneXpert MTB/RIF results compared to morning specimen in a programmatic setting in Cotonou, Benin
por: Massou, Faridath, et al.
Publicado: (2021)

Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: A case report from Uganda
por: Ssengooba, Willy, et al.
Publicado: (2021)

Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline
por: Villellas, Cristina, et al.
Publicado: (2017)

Retrospective Diagnostic Accuracy Study of Abbott RealTime MTB against Xpert MTB/RIF Ultra and Xpert MTB/RIF for the Diagnosis of Pulmonary Tuberculosis and Susceptibility to Rifampin and Isoniazid Treatment
por: Howlett, Patrick, et al.
Publicado: (2021)

Need to confirm isoniazid susceptibility in Xpert MTB/RIF rifampin susceptible cases
por: Vadwai, Viral, et al.
Publicado: (2012)

Bridging the TB data gap: in silico extraction of rifampicin-resistant tuberculosis diagnostic test results from whole genome sequence data
por: Ng, Kamela C. S., et al.
Publicado: (2019)

GeneXpert MTB/RIF Version G4 for Identification of Rifampin-Resistant Tuberculosis in a Programmatic Setting
por: Osman, Muhammad, et al.
Publicado: (2014)

Performance of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis and rifampin resistance in a low-incidence, high-resource setting
por: Rice, Jason P., et al.
Publicado: (2017)

Diagnostic performance of smear microscopy and incremental yield of Xpert in detection of pulmonary tuberculosis in Rwanda
por: Ngabonziza, Jean Claude Semuto, et al.
Publicado: (2016)

Case Report: Dynamics of Acquired Fluoroquinolone Resistance under Standardized Short-Course Treatment of Multidrug-Resistant Tuberculosis
por: Ngabonziza, Jean Claude Semuto, et al.
Publicado: (2020)

Assessing the utility of the Xpert Mycobacterium tuberculosis/rifampin assay for analysis of bronchoalveolar lavage fluid in patients with suspected pulmonary tuberculosis
por: Bai, Wenjing, et al.
Publicado: (2021)

Value of ultrasound guided biopsy combined with Xpert Mycobacterium tuberculosis/resistance to rifampin assay in the diagnosis of chest wall tuberculosis
por: Yan, Qing-Hu, et al.
Publicado: (2023)

Evaluation of Xpert(®) Mycobacterium tuberculosis/rifampin in sputum-smear negative and sputum-scarce patients with pulmonary tuberculosis using bronchoalveolar lavage fluid
por: Gowda, Nikhil C, et al.
Publicado: (2018)

Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults
por: Horne, David J, et al.
Publicado: (2019)

Genotypic characterization directly applied to sputum improves the detection of Mycobacterium africanum West African 1, under-represented in positive cultures
por: Sanoussi, C. N’Dira, et al.
Publicado: (2017)

Definitive outcomes in patients with rifampicin-resistant tuberculosis treated in Niger from 2012 to 2019: A retrospective cohort study
por: Souleymane, Mahamadou Bassirou, et al.
Publicado: (2022)

Unambiguous State Discrimination with Intrinsic Coherence
por: Zhang, Jin-Hua, et al.
Publicado: (2021)

Comparison of Analytical Sensitivity (Limit of Detection) of Xpert MTB/RIF and Xpert MTB/RIF Ultra for Non-Sputum Specimens
por: Nielsen, Marisa C., et al.
Publicado: (2023)

Utility of Xpert Ultra on Different Respiratory Specimens in Children
por: Jain, Saurav, et al.
Publicado: (2020)

Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults
por: Kohli, Mikashmi, et al.
Publicado: (2021)

Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children
por: Kay, Alexander W, et al.
Publicado: (2020)

Reconstituting the genus Mycobacterium
por: Meehan, Conor J., et al.
Publicado: (2021)

Etymologia: Rifampin
por: Henry, Ronnie
Publicado: (2018)

Comparison of tests done, and tuberculosis cases detected by Xpert® MTB/RIF and Xpert® MTB/RIF-Ultra in Uganda
por: Kakinda, Michael, et al.
Publicado: (2022)

Diagnostic accuracy of the Xpert MTB/Rif Ultra for tuberculosis adenitis
por: Antel, Katherine, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ukva3hgf3a5ehtrdqadl8546ev